hotspot -WSS

hotspot

author：comprehensive 2025-09-27 19:37:12 - browse：5892

Joe Biden in 2016. -- first opinion coverage from STAT — President Joe Biden Elise Amendola/AP

WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few questions on how Congress might move forward with the program.

Since its launch in 2016, the federally funded cancer moonshot program has spurred thousands of scientific publications, 49 clinical trials, and more than 30 patent filings, according to a new report from the Congressional Research Service, the nonpartisan research arm of Congress.

The next phase of the cancer moonshot, according to Biden and his administration, is meant to emphasize cancer screening, prevention, and equitable treatment. The updated plan also seeks to speed progress on treatments for rare and childhood cancers, and it calls for supporting patients, survivors, and caregivers. The Advanced Research Projects Agency for Health (ARPA-H), a new agency tasked with taking big risks on biomedical and health technology, is also committing $240 million to cancer-related research and investing in new data-sharing platforms and a nationwide network for clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： A new crop of companies is reshaping the health data economy

focus

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Readout Newsletter: Biotech news today

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Senate panel puts off hardest PBM reforms for another day

Is there really a nursing shortage in the U.S.?

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

leisure time

hotspot

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Walensky prepares to leave CDC — and Congress — behind

Smaller biotechs seek to piggyback on weight loss drug boom

Medicare proposal to cover medical devices draws a mixed reaction

What it's like to live with paralysis for one psychologist

Psychedelics group wrestles with new pharma identity

STAT Summit: Ending the crisis of Black deaths in the U.S.

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

New Alzheimer's drugs heat up race for early detection blood tests

leisure time

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Why patients can’t get everything they want on drug pricing

UnitedHealth, Optum discontinue NaviHealth name

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

CDC Director Mandy Cohen on transparency, trust, and health

Roche drug slashes death risk in early

hotspot

focus

entertainment

hotspot